id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-323024-blc3mnbj	Bernard-Valnet, R.	CSF of SARS-CoV-2 patients with neurological syndromes reveals hints to understand pathophysiology	2020-11-04		.txt	text/plain	3478	226	49	Methods: We checked for SARS-CoV-2 RNA by RT-qPCR, SARS-CoV-2-specific antibodies and for 48 cytokines/chemokines/growth factors (by Luminex) in the cerebrospinal fluids (CSF) +/sera of a cohort of 17 COVID-19 patients with neurological presentation and 55 neurological control patients (inflammatory [IND], non inflammatory [NIND], multiple sclerosis [MS]). Methods: We checked for SARS-CoV-2 mRNA by qPCR, SARS-CoV-2-specific antibodies and for 49 cytokines/chemokines/growth factors (by Luminex) in the cerebrospinal fluid (CSF) +/serum of a cohort of 17 COVID-19 patients with neurological presentation and 55 neurological controls (inflammatory, non inflammatory, multiple sclerosis). Thus, the main hypotheses to explain neurological complications in COVID patients point at mechanisms either related to low grade presence of the virus in the CNS, to cytokine storm or to the presence of an auto-immune response, such as anti-neuronal antibodies by analogy to what occurs in autoimmune encephalitis. We found that SARS-CoV-2 patients tend to have signs of blood brain barrier opening and possible astrocytes activation, but no strong immune response in the CSF or obvious CNS infection by the virus.	./cache/cord-323024-blc3mnbj.txt	./txt/cord-323024-blc3mnbj.txt